Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Pharnext to Host Research and Development Day  on October 13, 2020
Pharnext to Host Research and Development Day on October 13, 2020
Pharnext to Host Research and Development Day on October 13, 2020
DGAP-News: Abivax presents first-half 2020 financial results and operations update
DGAP-News: Abivax presents first-half 2020 financial results and operations update
DGAP-News: Abivax presents first-half 2020 financial results and operations update
DGAP-News: Abivax gibt Halbjahresergebnisse 2020 und Update zur Unternehmensentwicklung bekannt
DGAP-News: Abivax gibt Halbjahresergebnisse 2020 und Update zur Unternehmensentwicklung bekannt
DGAP-News: Abivax gibt Halbjahresergebnisse 2020 und Update zur Unternehmensentwicklung bekannt
Pharnext and the Charcot-Marie-Tooth Association  Enter Biomarker Research Collaboration
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Research Collaboration
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
DGAP-News: ABIVAX: Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
DGAP-News: Abivax gibt 2-Jahres-Daten zur Langzeitwirkung und Sicherheit aus der Phase-2a-Erhaltungsstudie mit ABX464 zur Behandlung von Colitis ulcerosa bekannt
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA: Information on Document Availability
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung  in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung  in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung  in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext provides regulatory and clinical update  on PXT3003 Phase III study  for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial